[Catamnestic studies in porphyria cutanea tarda with special reference to therapy].
D000227:Adenine Nucleotides / Q000627:therapeutic use*; D000255:Adenosine Triphosphate / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001815:Bloodletting; D003676:Deferoxamine / Q000627:therapeutic use*; D048909:Diabetes Complications; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011164:Porphyrias / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D011736:Pyridoxine / Q000627:therapeutic use*; D012256:Riboflavin / Q000627:therapeutic use*; D013588:Syphilis Serodiagnosis; D014805:Vitamin B 12 / Q000627:therapeutic use*; D014803:Vitamin B Complex / Q000627:therapeutic use*
D000227:Adenine Nucleotides; D014803:Vitamin B Complex; D000255:Adenosine Triphosphate; D003676:Deferoxamine; D011736:Pyridoxine; D014805:Vitamin B 12; D012256:Riboflavin
Katamnestische Untersuchungen bei Porphyria cutanea tarda unter besonderer Berücksichtigung der Therapie.